Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial.

Breast · 2026 · PMC13321393 · PMID 42364416

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

This analysis suggested a nonsignificant trend toward improved relapse-free survival with the DD approach in HER2-positive disease [ 11 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.